1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends

Generic Drug Opportunity Assessment : Apixaban (Eliquis)

  • January 2014
  • Greystone Research Associates
Report ID: 1973864


Greystone Research has identified a branded drug that represents an attractive opportunity for generic drug companies that utilize the provisions under Section 505(j)(2)(A)(vii)(IV) as part of their ANDA-filing strategy. Details of our findings are contained in an insightful assessment, the highlights if which are presented below.

The Brand

Eliquis (apixaban) is an oral Factor Xa inhibitor – essentially an anticoagulant - targeting stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic (VTE) disorders. It is currently approved in the EU, Canada and Japan for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors and for use in VTE prevention in adult patients who have undergone elective hip or knee surgery. In December 2012, the U.S. Food and Drug Administration (FDA) approved Eliquis to reduce the risk of stroke and systemic embolism in patients with NVAF.

The Drug

Apixaban is one of a group of novel oral anticoagulants (NOACs) that are more convenient, and are at least equally effective and safer (regarding bleeding complications) for stroke prevention compared with vitamin K antagonists (VKAs).

The Market

Atrial fibrillation (AF) increases the risk of stroke. The degree of increase can be substantial, depending on the presence of additional risk factors (such as high blood pressure). Atrial fibrillation may be treated with medications to either slow the heart rate to a normal range (rate control) or revert the heart rhythm to normal (rhythm control). The prevalence of AF in a population increases with age, with 8% of people over 80 having AF. Chronic AF leads to a small increase in the risk of death. Nonvalvular atrial fibrillation is AF in the absence of rheumatic mitral valve disease, a prosthetic heart valve, or mitral valve repair.

Patents & Exclusivity

The composition of matter patent covering apixaban in the U.S. expires in February 2023(excluding potential patent term extensions) and in the EU it expires in 2022. The Company has applied for supplementary protection certificates. Some of these supplementary protection certificates have been granted and expire in 2026. Data exclusivity in the EU expires in 2021. The composition of matter patent expires in Canada in 2022. Eliquis has been granted exclusivity by the FDA under the exclusivity code NCE (New Chemical Entity). This exclusivity expires on December 24, 2017. The FDA is precluded by law to approve any ANDA prior this date.

Therapeutic Sector P (IV) Activity

Until recently, the cardiovascular drug sector has been quite active with regard to ANDA filings, with P (IV) certifications averaging about five per year since 2006 - 2010. This trend reflects the fragmented therapeutic environment. We expect the rate of P (iV) certifications to increase through 2018, as brand drugs lose exclusivity and patent protection.

Market Dynamics

In terms of the overall market growth for novel oral anticoagulants, we expect Eliquis to overtake Pradaxa as the overall market segment leader in 2016. We are also forecasting total global Eliquis revenue to exceed US $4 billion for the year 2017. The result will be a highly attractive generic market for the ANDA first-filer prepared to enter the market at the end of 2017 when the FDA exclusivity period for Eliquis is scheduled to expire.

Generic Revenue Opportunity

We are predicting that the ANDA first-filer entering the market in will capture of the total global market for apixaban drugs for the treatment of AF in calendar year . The majority of sales will come during the 180-day exclusivity period, at a price approximately of the brand price.

Report Highlights

Eliquis – The Brand
Apixaban – The Market
Apixaban – The Opportunity
Manufacturing and Sourcing
Eliquis Patents and Exclusivity
Therapeutic Class P4 Certifications
Generic 1st-to-File Revenue Opportunity
Business Risk Assessment
First-to-File – Probabilistic Scenario

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Global Drug Eluting Balloons (DEBs) Market 2017-2021

  • $ 3500
  • Industry report
  • June 2017
  • by Infiniti Research Limited

About Drug Eluting Balloons A DEB, also known as a drug-coated balloon (DCB), is an advanced technology used in the treatment of coronary and peripheral arterial diseases. These diseases cause narrowing ...

Global Therapeutic Electrodes Market 2017-2021

  • $ 3500
  • Industry report
  • June 2017
  • by Infiniti Research Limited

About Therapeutic Electrodes Electrodes are electrical conductors that are capable of passing energy signals from a power source to a device or a material. Electrodes are made from metals such as zinc, ...

Global Mechanical Thrombectomy Devices Market 2017-2021

  • $ 3500
  • Industry report
  • June 2017
  • by Infiniti Research Limited

About Mechanical Thrombectomy Devices MIS procedures are rapidly becoming one of the leading approaches to treating various cardiovascular ailments, especially blood clots. The majority of the MIS are ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.